269.95
-3.30%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Infinium Pharmachem
Its shares trade on NSE under the ticker INFINIUM.NS. It has been listed since 17 April 2023. In the fiscal year to 31 March 2025, it reported revenue of ₹1.56bn and net income of ₹81.5m. At that date it held total assets of ₹1.98bn and shareholders' equity of ₹1.09bn.
Infinium Pharmachem Ltd. manufactures and supplies iodine derivatives. The company is headquartered in Vallabh Vidyanagar, Gujarat. The company went IPO on 2023-04-17. The firm is involved in the development, manufacture, and export of a spectrum of the Iodine Derivatives that are used in pharmaceutical, chemical, biotech and allied industries across the globe. The firm's portfolio includes approximately 200+ Iodine Derivatives and seven+ APIs. The company manufactures and supplies a range of Iodine based APIs, but on Order to Made basis only. The company offers bulk actives, intermediates and services for custom synthesis. The company also provides contract Research and manufacturing Services to the pharmaceutical and biotech companies for their diverse requirements of Iodine based APIs and intermediates to reduce their research time and project cost. The company manufactures iodine derivatives for the various industries, including pharmaceutical, chemical, nutraceutical, cosmetics, sanitation, agrochemical, electronics, Nylon production and other industries for their range of industrial applications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Apr 2023
- Website
- infiniumpharmachem.com ↗
Leadership
Pay as last reported
- Mr. Sanjaykumar PatelExecutive Chairman of the Board, Managing Director, since 2022₹5.0m
- Mr. Nilesh PatelChief Financial Officer, Compliance Officer, Company Secretary₹3.6m
- Mr. Mitesh ChikhaliyaExecutive Director₹5.0m
- Mr. Pravin MadhaniExecutive Director₹5.0m
- Mr. Tarun DobariyaNon-Executive Independent Director₹20,000
- Mr. Keyur ShahNon-Executive Independent Director₹20,000
- Ms. Vaishakhi ShuklaNon-Executive Independent Director₹20,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Infinium Pharmachem Ltd manufactures 200+ iodine derivatives for global pharmaceutical and chemical industries.
- The company offers seven+ APIs and custom synthesis services for pharmaceutical and biotech firms.
- Infinium Pharmachem Ltd provides bulk actives and intermediates for iodine-based applications across multiple sectors.
Weaknesses
- The company operates on an order-to-made basis for iodine derivatives limiting production scalability.
- Infinium Pharmachem Ltd has no presence in the consumer discretionary sector.
- The firm's focus on iodine derivatives restricts diversification into other chemical markets.
Opportunities
- Expanding iodine derivative applications in nutraceutical and cosmetics industries presents growth potential.
- Increasing demand for iodine-based APIs in agrochemical and electronics sectors offers new markets.
- The global pharmaceutical industry's reliance on iodine derivatives supports long-term market opportunities.
Threats
- Competition from other pharmaceutical companies in the iodine derivative market is a constant challenge.
- Fluctuations in raw material prices for iodine derivatives could impact profitability.
- Regulatory changes in the Health Care sector may affect the company's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.